盟科药业-U
(688373)
| 流通市值：40.57亿 | | | 总市值：50.61亿 |
| 流通股本：5.25亿 | | | 总股本：6.56亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 103,985,283.24 | 66,969,753.09 | 33,216,965.04 | 130,272,762.01 |
| 营业收入 | 103,985,283.24 | 66,969,753.09 | 33,216,965.04 | 130,272,762.01 |
| 二、营业总成本 | 304,175,409.85 | 209,906,680.34 | 96,412,359.38 | 581,598,318.57 |
| 营业成本 | 15,722,882.44 | 10,189,199.84 | 5,138,953.41 | 22,405,200.94 |
| 税金及附加 | 410,641.1 | 339,228.53 | 286,212.87 | 407,657.11 |
| 销售费用 | 67,787,383.65 | 48,488,509.1 | 22,406,451.74 | 110,491,483.35 |
| 管理费用 | 41,201,162.32 | 29,846,478.5 | 12,922,537.3 | 66,295,410.29 |
| 研发费用 | 172,747,166.04 | 116,413,285.79 | 53,852,131.73 | 368,564,368.34 |
| 财务费用 | 6,306,174.3 | 4,629,978.58 | 1,806,072.33 | 13,434,198.54 |
| 其中:利息费用 | 9,541,983.59 | 6,323,076.82 | 3,149,649.18 | 11,152,052.44 |
| 其中:利息收入 | 2,151,170.27 | 1,902,760.85 | 849,401.23 | 2,369,037.68 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 6,052,443.15 | 4,261,022.11 | 1,465,382.57 | 17,081,843.88 |
| 资产处置收益 | 3,387.23 | 4,427.63 | 49,427.63 | 27,456.31 |
| 信用减值损失(新) | -267,337.96 | -305,646.54 | -109,123.09 | -1,637,220.51 |
| 其他收益 | 1,485,848.11 | 905,168.65 | 158,286.61 | 1,364,746.04 |
| 四、营业利润 | -192,915,786.08 | -138,071,955.4 | -61,631,420.62 | -434,488,730.84 |
| 加:营业外收入 | 500 | 500 | - | - |
| 减:营业外支出 | 491,864.63 | 487,264.63 | 1,055.07 | 22,886.13 |
| 五、利润总额 | -193,407,150.71 | -138,558,720.03 | -61,632,475.69 | -434,511,616.97 |
| 减:所得税费用 | 128,996.55 | 115,772.52 | - | 6,209,600.12 |
| 六、净利润 | -193,536,147.26 | -138,674,492.55 | -61,632,475.69 | -440,721,217.09 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -193,536,147.26 | -138,674,492.55 | -61,632,475.69 | -440,721,217.09 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -193,536,147.26 | -138,674,492.55 | -61,632,475.69 | -440,721,217.09 |
| 扣除非经常损益后的净利润 | -200,586,461.12 | -143,358,346.31 | -63,304,517.43 | -459,172,377.19 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.3 | -0.21 | -0.09 | -0.67 |
| (二)稀释每股收益 | -0.3 | -0.21 | -0.09 | -0.67 |
| 八、其他综合收益 | -5,117,441.93 | -2,175,638.72 | -816,039.59 | 6,175,113.78 |
| 归属于母公司股东的其他综合收益 | -5,117,441.93 | -2,175,638.72 | -816,039.59 | 6,175,113.78 |
| 九、综合收益总额 | -198,653,589.19 | -140,850,131.27 | -62,448,515.28 | -434,546,103.31 |
| 归属于母公司股东的综合收益总额 | -198,653,589.19 | -140,850,131.27 | -62,448,515.28 | -434,546,103.31 |
| 公告日期 | 2025-10-28 | 2025-08-20 | 2025-04-24 | 2025-03-18 |
| 审计意见(境内) | | | | 标准无保留意见 |